124 related articles for article (PubMed ID: 37713954)
1. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma.
Stockhammer P; Baumeister H; Ploenes T; Bonella F; Theegarten D; Dome B; Pirker C; Berger W; Hegedüs L; Baranyi M; Schuler M; Deshayes S; Bölükbas S; Aigner C; Blanquart C; Hegedüs B
Lung Cancer; 2023 Nov; 185():107360. PubMed ID: 37713954
[TBL] [Abstract][Full Text] [Related]
2. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer.
Wang J; Ling L; Chen S; Chou L; Wang Y; Hu L
Lab Med; 2024 May; 55(3):271-276. PubMed ID: 37566516
[TBL] [Abstract][Full Text] [Related]
4. A case of pleural mesothelioma with immunohistochemical staining positive for Krebs von den Lungen-6.
Matsumura Y; Sato S; Haji K; Masuda T; Yoneda H; Ogino H; Ogawa H; Hanibuchi M; Hattori N; Nishioka Y
Respir Med Case Rep; 2024; 50():102040. PubMed ID: 38803368
[TBL] [Abstract][Full Text] [Related]
5. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
Sorino C; Mondoni M; Marchetti G; Agati S; Inchingolo R; Mei F; Flamini S; Lococo F; Feller-Kopman D
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002620
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
7. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer.
Tanaka S; Hattori N; Ishikawa N; Shoda H; Takano A; Nishino R; Okada M; Arihiro K; Inai K; Hamada H; Yokoyama A; Kohno N
Int J Cancer; 2012 Jan; 130(2):377-87. PubMed ID: 21351094
[TBL] [Abstract][Full Text] [Related]
8. Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression.
Sato S; Kato T; Abe K; Hanaoka T; Yano Y; Kurosaki A; Yasuda M; Sekino T; Fujiwara K; Hasegawa K
Oncol Lett; 2017 Jul; 14(1):776-786. PubMed ID: 28693233
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
10. Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score.
Grosso F; Mannucci M; Ugo F; Ferro P; Cassinari M; Vigani A; De Angelis AM; Delfanti S; Lia M; Guaschino R; Barbero S; Roncella S; Giannoni U; Bertolotti M; Pistillo MP; Fontana V
Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829362
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serum Krebs von den Lungen-6 (KL-6) levels in COVID-19 pneumonia.
Letellier A; Rolland-Debord C; Luque-Paz D; Milon A; Choinier P; Blin E; Halitim P; Bravais J; Lefèvre G; Parrot A; Piéroni L; Cadranel J
Respir Med Res; 2023 Nov; 84():101054. PubMed ID: 37897878
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of pleural fluid SMRP, CA125, MMP-7, and MMP-9 in malignant pleural effusion.
Han G; Li J; Liu X; Guo R
Medicine (Baltimore); 2023 Jan; 102(4):e32759. PubMed ID: 36705352
[TBL] [Abstract][Full Text] [Related]
16. Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.
d'Alessandro M; Bergantini L; Cavallaro D; Gangi S; Cameli P; Conticini E; Siena Covid Unit ; Frediani B; Dotta F; Bargagli E
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206372
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
[TBL] [Abstract][Full Text] [Related]
18. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract][Full Text] [Related]
20. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
